COPD pathophysiology: a complete nursing reference guide

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide and one of the most common respiratory conditions you will manage as a nurse. Understanding COPD pathophysiology is critical because it explains every clinical finding – from barrel chest to hypercapnia – and drives every nursing intervention, from oxygen titration to medication sequencing.

This reference covers the full picture: disease mechanisms, GOLD staging, the classic pink puffer versus blue bloater distinction, nursing assessments, pharmacology with nursing considerations, and the NCLEX-critical oxygen therapy concepts that trip up students. Use this alongside the nursing lab values cheat sheet and the heart failure reference – right-sided heart failure is a common COPD complication.

What is COPD?

COPD is a chronic inflammatory lung disease that causes progressive, largely irreversible airflow obstruction. It is an umbrella term covering two overlapping conditions: emphysema and chronic bronchitis. Most patients have features of both, though one component may dominate.

• Emphysema involves destruction of the alveolar walls (the gas-exchange surface), leading to enlarged air spaces, loss of elastic recoil, and air trapping. The lung cannot efficiently push air out during exhalation.
• Chronic bronchitis is defined clinically as a productive cough present for at least three months in each of two consecutive years (after other causes are excluded). Inflammation and mucus hypersecretion narrow the airways and obstruct airflow.

COPD affects approximately 213 million people globally (Global Burden of Disease Study 2021) and caused 3.4 million deaths in 2023 according to the WHO. In the United States, more than 15 million adults report a COPD diagnosis, and millions more are thought to be undiagnosed; CDC/NCHS put the age-adjusted prevalence of diagnosed COPD among adults 18 and older at 3.8% in 2023, rising to 10.5% in those aged 75 and older. Tobacco smoking is the single largest risk factor: in GBD 2021 it accounted for 34.8% of global COPD disability-adjusted life years (DALYs), followed by ambient particulate matter pollution (22.2%), household air pollution from solid fuels (19.5%), and occupational particulates, gases, and fumes (15.8%). Taken together, the two air-pollution exposures outweigh smoking worldwide, which is why WHO attributes over 70% of cases in high-income countries to smoking but only 30–40% in low- and middle-income countries. Other risk factors include alpha-1 antitrypsin (AAT) deficiency, and a history of childhood respiratory infections.

Pathophysiology: how airflow obstruction develops

The pathophysiology of COPD centers on chronic inflammation that progressively damages airways and lung parenchyma. Understanding the mechanism explains why COPD is irreversible and why specific interventions work.

The inflammatory cascade

Inhaled irritants – most commonly cigarette smoke – trigger a chronic inflammatory response in the lungs. Neutrophils, macrophages, and CD8+ T lymphocytes infiltrate the airway walls and lung tissue. These cells release proteases (especially neutrophil elastase and matrix metalloproteinases) and oxidants that break down structural proteins, particularly elastin.

In healthy lungs, antiproteases like alpha-1 antitrypsin neutralize proteases and prevent tissue damage. In COPD, the protease-antiprotease balance shifts decisively toward destruction. Oxidative stress from smoke further inactivates protective antiproteases and amplifies inflammation. This is the protease-antiprotease imbalance that drives emphysematous destruction.

Airflow obstruction mechanisms

COPD causes airflow obstruction through several simultaneous mechanisms:

1. Alveolar wall destruction (emphysema). Loss of alveolar septa reduces the elastic recoil that normally holds small airways open during exhalation. Without this tethering force, small airways collapse during expiration, trapping air distally.
2. Airway inflammation and remodeling (chronic bronchitis). Chronic inflammation causes goblet cell hyperplasia, mucus hypersecretion, smooth muscle hypertrophy, and fibrotic thickening of the airway wall. The bronchial lumen narrows, increasing resistance to airflow.
3. Mucus plugging. Excess, tenacious mucus physically blocks smaller airways, further reducing airflow and creating a breeding ground for bacterial colonization.

Air trapping and hyperinflation

Because damaged airways collapse during exhalation, air becomes trapped in the distal alveoli. With each breath, more air enters than leaves – this is dynamic hyperinflation. The lungs progressively over-expand, pushing the diaphragm downward and flattening it. A flattened diaphragm contracts inefficiently, which is why COPD patients recruit accessory muscles (sternocleidomastoid, scalenes, intercostals) to breathe.

Hyperinflation is the direct cause of barrel chest – the increased anteroposterior diameter visible on inspection and measurable on chest X-ray.

Gas exchange failure

Alveolar destruction reduces the surface area available for oxygen and carbon dioxide exchange. Mucus plugging and airway narrowing create ventilation-perfusion (V/Q) mismatch – some lung regions are perfused but poorly ventilated, leading to hypoxemia (low PaO2).

As the disease progresses, CO2 elimination also fails, producing hypercapnia (elevated PaCO2). The body compensates through renal retention of bicarbonate (HCO3-), which is why chronic COPD patients often show a compensated respiratory acidosis on arterial blood gas (ABG): elevated PaCO2, elevated HCO3-, and a near-normal pH.

Pulmonary hypertension and cor pulmonale

Chronic hypoxemia causes pulmonary arteriolar vasoconstriction (hypoxic pulmonary vasoconstriction). Over time, this remodels the pulmonary vasculature and raises pulmonary artery pressure. The right ventricle, which normally operates at low pressures, must work progressively harder against this increased afterload. This leads to right ventricular hypertrophy and eventually right-sided heart failure – cor pulmonale. Signs include jugular venous distension (JVD), peripheral edema, and hepatomegaly. See the heart failure nursing reference for a deeper look at right-sided failure management.

Pink puffers vs blue bloaters

These classic COPD phenotypes describe the two extremes of the clinical spectrum. While most patients have a mixed presentation, understanding these archetypes is high-yield for NCLEX and helps explain the underlying pathophysiology.

Clinical reality: Most patients present with features of both phenotypes. The GOLD guidelines and current clinical practice have moved away from this binary classification toward individualized assessment. However, the distinction remains a valuable teaching tool and appears frequently on nursing exams.

Clinical presentation and physical exam findings

Recognizing COPD on assessment requires connecting physical findings to the underlying pathophysiology.

Respiratory findings:

• Dyspnea – progressive, worse with exertion, eventually present at rest. This is the hallmark symptom.
• Chronic cough – may be productive (chronic bronchitis) or dry (emphysema). Morning cough with sputum is classic for chronic bronchitis.
• Wheezing – from narrowed, inflamed airways. May worsen during exacerbations.
• Prolonged expiratory phase – because air has difficulty leaving obstructed airways.

Inspection findings:

• Barrel chest – increased anteroposterior diameter from chronic hyperinflation.
• Pursed-lip breathing – a compensatory technique that creates back-pressure to keep airways open during exhalation, improving gas exchange.
• Accessory muscle use – sternocleidomastoid, scalene, and intercostal muscles recruited when the flattened diaphragm cannot generate adequate ventilation.
• Tripod positioning – patient leans forward with hands on knees or table. This position stabilizes the shoulder girdle and optimizes accessory muscle mechanics.
• Digital clubbing – not a typical finding in COPD alone. New clubbing in a patient with COPD should be reported, because it can point to a second diagnosis such as lung cancer, bronchiectasis, or interstitial lung disease.
• Cyanosis – bluish discoloration of lips and nail beds. Central cyanosis is a late sign of hypoxemia: it usually becomes visible only when saturation falls to around 85% or lower, appears later still in anemia, and earlier in polycythemia. Do not wait for cyanosis before acting on a low SpO2.

Auscultation:

• Diminished breath sounds (air trapping reduces sound transmission)
• Wheezes and rhonchi (narrowed airways)
• Crackles may be present, especially with concurrent infection or heart failure

GOLD staging

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) classifies COPD severity by post-bronchodilator FEV1 (forced expiratory volume in one second) compared to the predicted normal value for age, sex, and height. This staging guides treatment escalation.

Diagnostic confirmation requires spirometry showing a post-bronchodilator FEV1/FVC ratio < 0.70. This distinguishes COPD from asthma, where airflow obstruction is typically reversible with bronchodilators.

The current GOLD framework also uses an ABE assessment tool (replacing the former ABCD groups) that combines symptom burden (measured by CAT score or mMRC dyspnea scale) and exacerbation history to guide pharmacotherapy decisions. A patient can be GOLD stage 2 by spirometry but group E by exacerbation history – both matter for treatment planning. The 2026 GOLD report (version 1.3, December 2025) moves group E to include people with a single moderate exacerbation in the previous year, because observational data show that even one moderate or severe exacerbation raises the risk of further events. The same one-exacerbation threshold now prompts consideration of treatment escalation, with the aim of a low disease-activity state: no exacerbations, no worsening of symptoms, and low symptom impact.

Diagnostics

Spirometry

Spirometry is the gold standard for COPD diagnosis. The key measurements:

• FEV1 – volume of air exhaled in the first second of a forced expiration.
• FVC – total volume of air exhaled during a forced expiration.
• FEV1/FVC ratio – a ratio < 0.70 after bronchodilator administration confirms obstructive disease.
• Post-bronchodilator testing – spirometry is repeated after inhaled bronchodilator (typically albuterol 400 mcg). If obstruction persists (FEV1/FVC still < 0.70), this points to COPD rather than reversible asthma.

Arterial blood gas (ABG) patterns

ABGs reveal the gas exchange consequences of COPD and are essential for guiding oxygen therapy.

The elevated bicarbonate is the kidney’s response to chronically elevated CO2 – it retains HCO3- to buffer the acidosis and maintain near-normal pH. This compensation takes days to develop, which is why it indicates chronic (not acute) hypercapnia.

Chest X-ray

CXR findings in COPD include hyperinflated lung fields, flattened diaphragms, increased retrosternal air space, and a narrow, elongated cardiac silhouette (in emphysema). CXR is used to rule out other diagnoses (pneumonia, lung cancer, pleural effusion) rather than to confirm COPD.

Additional diagnostics

• CBC – may show polycythemia (elevated RBC/hematocrit) as a compensatory response to chronic hypoxemia.
• Alpha-1 antitrypsin level – GOLD 2026 recommends testing every patient with a COPD diagnosis once. The classic picture is a young patient (under 45) with lower-lobe emphysema, but many cases are found later in patients who look like typical COPD.
• Blood eosinophil count – part of the routine CBC, it now guides therapy: inhaled corticosteroids help most at 300 cells/µL or higher and have little or no effect below 100 cells/µL.
• BNP/NT-proBNP – to evaluate for concurrent heart failure, especially when dyspnea worsens acutely. Review normal values on the lab values cheat sheet.

Nursing assessment priorities

Nursing assessment in COPD focuses on respiratory status, oxygenation, and early detection of exacerbations.

Every shift (or more frequently during exacerbations):

1. Respiratory rate, depth, and pattern. Tachypnea (RR > 20) and prolonged expiration signal worsening obstruction. Refer to the vital signs by age reference for baseline ranges.
2. Oxygen saturation. Continuous pulse oximetry for hospitalized patients. Target SpO2 88–92% in patients with known COPD or other risk factors for hypercapnia until a blood gas is available, then follow the target the team sets from the PaCO2.
3. Breath sounds. Auscultate all lobes. Note diminished sounds, new wheezing, or crackles. Absent breath sounds in a previously wheezing patient may indicate complete airway obstruction – this is an emergency.
4. Work of breathing. Accessory muscle use, nasal flaring, tripod positioning, and inability to speak in full sentences all indicate respiratory distress.
5. Cough and sputum. Character, color, volume, and consistency. A change from clear/white to yellow/green/purulent suggests infection. Increased volume suggests exacerbation.
6. Mental status. CO2 narcosis presents as confusion, somnolence, and decreased responsiveness. Acute mental status change in a COPD patient warrants immediate ABG and clinical escalation.

Daily assessments:

• Weight (fluid retention from cor pulmonale)
• Peripheral edema (ankles, sacrum)
• JVD (right-sided heart failure)
• Nutritional intake (COPD patients are often cachectic due to increased caloric expenditure from labored breathing)

Nursing interventions

Positioning

• High Fowler’s position (60–90°) maximizes lung expansion by allowing the diaphragm to descend fully.
• Tripod position – patient sits upright leaning forward with arms supported on a table or knees. This stabilizes the thorax and optimizes accessory muscle use. Teach patients to use this position during dyspnea episodes at home.
• Avoid supine positioning – this allows abdominal contents to push up against the diaphragm, reducing lung expansion.

Oxygen therapy: why COPD patients get a lower target

This is one of the most tested COPD concepts in nursing education, and the explanation most textbooks give for it is incomplete.

The classic teaching. In healthy people, rising PaCO2 acting on central chemoreceptors in the brainstem is the main stimulus to breathe. The traditional “hypoxic drive” theory holds that chronic CO2 retainers lose this response and depend on low PaO2 sensed by the peripheral chemoreceptors (carotid and aortic bodies), so giving oxygen removes their stimulus to breathe.

What the evidence shows. The British Thoracic Society (BTS) 2017 emergency oxygen guideline reviews this physiology and concludes that reduced drive is a small contributor. When Aubier and colleagues gave 100% oxygen to COPD patients in acute respiratory failure, minute ventilation fell by an average of 18% at first and recovered to 93% of baseline within 15 minutes, yet PaCO2 still rose by about 23 mmHg; the authors attributed the rise mainly to worsening ventilation-perfusion (V/Q) matching. BTS ranks the likely mechanisms of oxygen-induced hypercapnia in this order:

1. V/Q mismatch. Poorly ventilated lung units are normally poorly perfused because of hypoxic pulmonary vasoconstriction. High-concentration oxygen releases that vasoconstriction, sending more blood through units that cannot clear CO2.
2. Reduced ventilatory drive. Ventilation does fall as hypoxemia is corrected, but raising PaO2 above about 100 mmHg has little further effect on ventilation, while PaCO2 keeps climbing.
3. The Haldane effect. Oxygenated hemoglobin carries less CO2, so more CO2 is released into the plasma.
4. Absorption atelectasis, followed by the higher density of oxygen and rebreathing from a face mask run at too low a flow.

Why it matters. Whatever the mechanism, the danger is real. Uncontrolled high-concentration oxygen can push PaCO2 up and pH down, leading to worsening respiratory acidosis, CO2 narcosis, and respiratory failure. BTS estimates that 20–50% of patients with a COPD exacerbation or obesity hypoventilation are at risk of CO2 retention with excessive oxygen. In a prehospital randomized trial (Austin 2010), titrating oxygen to SpO2 88–92% cut mortality by 78% compared with high-flow oxygen in patients with confirmed COPD.

The clinical guideline (BTS 2017):

• Target SpO2 88–92% in patients with known COPD or other risk factors for hypercapnic respiratory failure, pending blood gas results.
• Before blood gases are available, start with a 24% Venturi mask at 2–3 L/min, a 28% Venturi mask at 4 L/min, or nasal cannula at 1–2 L/min.
• Check an ABG. If the PaCO2 is normal and the patient has no history of hypercapnic respiratory failure needing NIV or intubation, the target can move to 94–98%. Recheck blood gases 30–60 minutes after any change.
• A COPD patient who is critically ill (shock, major trauma, cardiac arrest) starts on the same high-concentration oxygen as any other critically ill patient until blood gases guide the target.
• Never stop oxygen abruptly in a patient who has become hypercapnic on high-flow oxygen. Step it down to the target range: sudden withdrawal can cause rebound hypoxemia worse than the starting level.

GOLD recommends controlled oxygen therapy for hypoxemic exacerbations, and the BTS guideline supplies the 88–92% number. Never withhold oxygen from a hypoxemic patient: titrate it.

Breathing techniques

• Pursed-lip breathing. Patient inhales through the nose (2 counts) and exhales slowly through pursed lips (4 counts). This creates positive back-pressure in the airways, preventing premature airway collapse during exhalation, reducing air trapping, and improving gas exchange. Teach this as a self-management tool for dyspnea episodes.
• Diaphragmatic breathing. Patient places one hand on the chest and one on the abdomen. On inhalation, the abdomen should rise while the chest stays relatively still. This promotes efficient diaphragm use and reduces reliance on accessory muscles.

Airway clearance

• Encourage adequate hydration (thins secretions unless fluid-restricted for heart failure).
• Teach effective coughing: deep breath in, hold briefly, cough forcefully from the diaphragm (huff coughing).
• Chest physiotherapy and postural drainage for patients with copious secretions.
• Suctioning as needed for patients who cannot clear secretions independently.

Medications and nursing considerations

COPD pharmacotherapy is chosen by ABE group (symptoms and exacerbation history) and then adjusted at follow-up, rather than by spirometric GOLD grade. Understanding the drug classes and their nursing implications is essential for safe practice and NCLEX preparation.

Inhaler sequencing: When a patient uses both a bronchodilator and an inhaled corticosteroid, administer the bronchodilator first. Wait 5 minutes, then use the ICS. The bronchodilator opens the airways, allowing the corticosteroid to reach deeper into the lungs. Refer to the drug classifications nursing guide for broader pharmacology context.

Patient education priorities

Effective patient education reduces exacerbations, hospital readmissions, and mortality in COPD. These are the key teaching points:

Smoking cessation. This is the single most important intervention to slow COPD progression. Discuss nicotine replacement therapy (patch, gum, lozenge), prescription options (varenicline, bupropion), and behavioral counseling. Every encounter is an opportunity to reinforce cessation.

Inhaler technique. Incorrect inhaler use is extremely common and directly reduces medication effectiveness. Demonstrate proper technique for each device type (MDI, DPI, soft mist inhaler). Have the patient return-demonstrate. Reassess technique at every visit. Key points: shake MDI before use, exhale fully before inhalation, coordinate actuation with inhalation (or use a spacer), hold breath for 10 seconds after inhalation, rinse mouth after ICS use.

Pulmonary rehabilitation. A structured program of exercise training, education, and behavioral modification that improves exercise capacity, symptoms, and quality of life across all grades of COPD severity (GOLD 2026). Starting it during a hospital stay or within 4 weeks of discharge after an exacerbation is linked to lower mortality. Encourage patients to ask their provider about referral.

Vaccinations. Current recommendations include annual influenza vaccine and pneumococcal vaccination. CDC recommends a single dose of a pneumococcal conjugate vaccine – PCV15, PCV20, or PCV21 – for all PCV-naive adults aged 50 and older, and for adults 19 to 49 with chronic lung disease such as COPD. If PCV15 is the dose given, follow it with PPSV23 at least one year later. RSV vaccination is recommended for everyone 75 and older and for adults 50 to 74 with chronic lung disease. Add COVID-19 vaccination per current guidelines and Tdap if not previously received. Respiratory infections are the most common trigger for COPD exacerbations.

Recognizing exacerbation signs. Teach patients to seek care for increased dyspnea beyond their normal baseline, change in sputum color or volume, fever, increased cough, confusion or excessive drowsiness, and inability to perform daily activities. Patients with an action plan who recognize exacerbations early have better outcomes.

Energy conservation. Plan activities with rest periods. Sit during tasks when possible. Use assistive devices for ambulation. Eat small, frequent, high-calorie meals – large meals push the diaphragm upward and worsen dyspnea. Many COPD patients benefit from nutritional supplementation to combat weight loss from increased work of breathing.

NCLEX tips: high-yield COPD concepts

These are the distinctions and concepts most likely to appear on the NCLEX and nursing school exams:

1. Oxygen target in COPD: 88–92% SpO2. This is the most tested COPD concept. On exam items about a CO2 retainer, uncontrolled high-concentration oxygen is the wrong answer and low-flow (1–2 L/min via nasal cannula) or controlled FiO2 (Venturi mask at 24–28%) is correct. Withholding oxygen from a hypoxemic patient is also wrong. If an item asks why, the best-supported answer is that high-concentration oxygen worsens V/Q matching; loss of hypoxic drive is a smaller contributor.

2. Pink puffer = emphysema, blue bloater = chronic bronchitis. The classic distinction. Pink puffers hyperventilate to maintain oxygenation (hence pink). Blue bloaters are cyanotic and edematous from hypoxemia and cor pulmonale. Know the table above – this is high-yield.

3. Bronchodilator before steroid inhaler. When the two are separate devices, the bronchodilator goes first so the steroid can penetrate deeper. If a question asks about the order of medications, bronchodilator comes first with a 5-minute wait. Many COPD patients now use a single combination inhaler, where the question does not arise.

4. Rinse mouth after ICS. Prevents oral candidiasis (thrush). If a patient on inhaled steroids develops white patches on the oral mucosa, suspect thrush and teach proper rinsing.

5. Theophylline: narrow therapeutic index. Many textbooks quote 10–20 mcg/mL; the current label advises a peak of 10–15 mcg/mL, with toxicity more likely above 20. Signs of toxicity: nausea, vomiting, restlessness, seizures, cardiac arrhythmias. Check drug levels regularly. Many drug interactions raise theophylline levels.

6. FEV1/FVC < 0.70 = obstructive disease. A post-bronchodilator ratio below 0.70 confirms persistent obstruction in a patient with symptoms or exposures. If the ratio normalizes after bronchodilator, COPD is excluded by this criterion; that points toward asthma or another diagnosis but does not confirm asthma on its own.

7. Pursed-lip breathing is a key self-management tool. It prevents airway collapse during exhalation, reduces air trapping, and improves oxygenation. Teach it to every COPD patient.

8. Smoking cessation is the single most important intervention. No medication, therapy, or intervention slows COPD progression as effectively as quitting smoking. This is the correct answer when a question asks about the most important recommendation.

9. Acute exacerbation priority: ABCs. Assess airway, breathing, circulation. Check ABG. Give controlled oxygen. Administer short-acting bronchodilators. Assess for triggers (infection, non-adherence). Corticosteroids (prednisone 40 mg daily for 5 days per GOLD). Antibiotics if bacterial infection is suspected. Noninvasive ventilation is the first-line support for acute hypercapnic respiratory failure.

10. Cor pulmonale is right-sided heart failure from COPD. Look for JVD, peripheral edema, hepatomegaly, and elevated CVP. It develops because chronic hypoxemia causes pulmonary hypertension, which overloads the right ventricle.

Related references

Build your respiratory and cardiac reference library with these complementary guides:

• Heart failure pathophysiology nursing reference – cor pulmonale from COPD leads to right-sided heart failure. This guide covers pathophysiology, assessment, and nursing priorities for heart failure.
• Nursing lab values cheat sheet – ABG interpretation, BNP levels, CBC values, and other labs relevant to COPD management.
• Vital signs by age – baseline respiratory rate ranges for recognizing tachypnea in COPD patients.
• EKG interpretation cheat sheet – right heart strain patterns and arrhythmias associated with COPD and cor pulmonale.
• Drug classifications nursing guide – broader pharmacology reference including bronchodilators and corticosteroids.

References

[1]. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2026 Report (version 1.3, December 8, 2025). GOLD; 2026. https://goldcopd.org/2026-gold-report/

[2]. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease (TORCH trial). N Engl J Med. 2007;356(8):775–789. doi:10.1056/NEJMoa063070

[3]. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). N Engl J Med. 2008;359(15):1543–1554. doi:10.1056/NEJMoa0805800

[4]. Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD (IMPACT trial). N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901

[5]. Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD (FLAME trial). N Engl J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa1516385

[6]. (Historical, superseded by ref 1.) Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365. doi:10.1164/rccm.201204-0596PP

[7]. Wedzicha JA, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;49(3):1600791. doi:10.1183/13993003.00791-2016

[8]. World Health Organization. Chronic obstructive pulmonary disease (COPD). WHO Fact Sheet. Updated June 2026. https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)

[9]. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370(9589):765–773. doi:10.1016/S0140-6736(07)61380-4

[10]. (Historical, superseded by ref 1.) Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532–555. doi:10.1164/rccm.200703-456SO

[11]. O’Donnell DE, Laveneziana P. Dyspnea and activity limitation in COPD: mechanical factors. COPD. 2007;4(3):225–236. doi:10.1080/15412550701480455

[12]. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA. 1994;272(19):1497–1505. doi:10.1001/jama.1994.03520190043033

[13]. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012;379(9823):1341–1351. doi:10.1016/S0140-6736(11)60968-9

[14]. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.00102509

[15]. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;(2):CD003793. doi:10.1002/14651858.CD003793.pub3

[16]. Wang Z, Lin J, Liang L, et al. Global, regional, and national burden of chronic obstructive pulmonary disease and its attributable risk factors from 1990 to 2021: an analysis for the Global Burden of Disease Study 2021. Respir Res. 2025;26(1):2. doi:10.1186/s12931-024-03051-2

[17]. Weeks JD, Elgaddal N. Chronic obstructive pulmonary disease in adults age 18 and older: United States, 2023. NCHS Data Brief. 2025 May;(529):1–9.

[18]. Agustí A, Celli BR, Criner GJ, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD executive summary. Am J Respir Crit Care Med. 2023;207(7):819–837. doi:10.1164/rccm.202301-0106PP

[19]. O’Driscoll BR, Howard LS, Earis J, Mak V. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017;72(Suppl 1):ii1–ii90. doi:10.1136/thoraxjnl-2016-209729

[20]. Austin MA, Wills KE, Blizzard L, Walters EH, Wood-Baker R. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ. 2010;341:c5462. doi:10.1136/bmj.c5462

[21]. Aubier M, Murciano D, Milic-Emili J, et al. Effects of the administration of O2 on ventilation and blood gases in patients with chronic obstructive pulmonary disease during acute respiratory failure. Am Rev Respir Dis. 1980;122(5):747–754. doi:10.1164/arrd.1980.122.5.747

[22]. Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389(3):205–214. doi:10.1056/NEJMoa2303951

[23]. Sciurba FC, Criner GJ, Christenson SA, et al. Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype. N Engl J Med. 2025;392(17):1710–1720. doi:10.1056/NEJMoa2413181

[24]. Anzueto A, Barjaktarevic IZ, Siler TM, et al. Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE trials). Am J Respir Crit Care Med. 2023;208(4):406–416. doi:10.1164/rccm.202306-0944OC

[25]. US National Library of Medicine. DailyMed prescribing information: Atrovent HFA (ipratropium bromide), rev. 11/2025; Daliresp (roflumilast), rev. 12/2025; Theo-24 (theophylline), rev. 7/2024; Ohtuvayre (ensifentrine), rev. 5/2026. Accessed October 9, 2026. https://dailymed.nlm.nih.gov/

[26]. Centers for Disease Control and Prevention. Pneumococcal vaccine recommendations (updated February 25, 2026) and risk-based recommendations (updated May 8, 2026). Accessed October 9, 2026. https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html